Are the side effects of Trelagliptin serious?

Trelagliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, offers a convenient once-weekly oral regimen in the management of type 2 diabetes. Its mechanism of action is mainly by prolonging the activity of the insulin-secreting hormones GLP-1 and GIP, promoting the secretion of insulin by pancreatic beta cells, and at the same time inhibiting the excessive increase in blood sugar after meals in diabetic patients. Compared with traditional daily oral antidiabetic drugs, the once-weekly administration of trolagliptin improves patient compliance and reduces the impact of drug fluctuations on glycemic control.

In terms of safety, clinical studies and overseas post-marketing drug monitoring data show that the side effects of trolagliptin are generally mild and the incidence is lower than that of some other oral hypoglycemic drugs. The most common adverse reactions include mild gastrointestinal symptoms, such as nausea, abdominal discomfort, or mild diarrhea. These reactions are mostly transient, usually occur early in treatment and resolve spontaneously. A small number of patients may develop upper respiratory tract infection, headache or joint pain, and most of these symptoms can be continued without discontinuation of medication.

Compared with sulfonylureas or insulin, the biggest advantage of trolagliptin's low risk is that the incidence of hypoglycemic events is very low, especially when used alone or in combination with non-insulin antidiabetic drugs, it is safer. It should be noted that although DPP-4 inhibitors are generally well tolerated in long-term use, there are still rare cases of pancreatitis or severe rash. Therefore, you should pay attention to abdominal pain, persistent vomiting or skin abnormalities during medication, and deal with them in a timely manner under the guidance of a doctor.

In general, trotagliptin has mild side effects and good safety, and is especially suitable for patients with type 2 diabetes who want to reduce their daily drug burden. Combined with diet control and exercise therapy, trotagliptin can provide a stable and sustainable blood sugar management solution, while reducing the risk of hypoglycemia and improving patients' quality of life. In clinical practice, regular follow-up and monitoring of blood glucose and related experimental indicators are still the key to ensuring the safety and efficacy of medication.

Reference materials:https://en.wikipedia.org/wiki/Trelagliptin